Pear Therapeutics (Nasdaq:PEAR) today announced data from two studies that highlight the effectiveness of its chronic insomnia treatment.
Boston-based Pear Therapeutics designed its Somryst prescription digital therapeutic (PDT) to address the underlying issues of chronic insomnia by delivering cognitive behavioral therapy for insomnia (CBTi), training the body to sleep. The nine-week PDT can be used on a mobile device, such as a smartphone or tablet as the only FDA-authorized therapeutic that delivers guideline-recommended first-line treatment for chronic insomnia.
Get the full story at our sister site, Drug Delivery Business News.